3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
87
Carboplatin
58
Cyclophosphamide
57
Specimen Handling
54
fludarabine
45
Nivolumab
44
Magnetic Resonance Spectroscopy
43
Gemcitabine
41
Biopsy
39
Bevacizumab
36
venetoclax
34
Dexamethasone
32
Paclitaxel
29
Pemetrexed
28
Injections
28
Cisplatin
28
Docetaxel
26
atezolizumab
22
Ipilimumab
22
Capecitabine
22
Temozolomide
21
Rituximab
21
Oxaliplatin
21
Azacitidine
21
Cetuximab
20
Lenalidomide
19
Fulvestrant
19
abemaciclib
18
Fluorouracil
18
Cytarabine
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Histamine Antagonists
×
90 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled